Type 1 diabetes

#Autoimmune disease #etherna #mRNA #Multiple sclerosis #Type 1 diabetes

mRNA technology could treat autoimmune diseases, study shows

mRNA technology could help treat autoimmune diseases such as multiple sclerosis and type 1 diabetes, researchers say.  Scientists at the Biomedical Research Institute (BIOMED) at Hasselt University and the Belgian biotech company etherna have demonstrated that mRNA technology, which gained recognition for its use in Covid-19 vaccines, also holds promise for the targeted… Read More

#Editor's Choice #News

Patient with type 1 diabetes
#FDA #Sanofi #Type 1 diabetes

FDA expedites review of Sanofi’s Type 1 diabetes drug

The US Food and Drug Administration (FDA) has accepted Sanofi’s Stage 3 Type 1 diabetes drug, Tzield, for expedited review.  Tzield delays the progression of Stage 3 Type 1 diabetes (T1D) in patients eight years or older who have recently been diagnosed. Sanofi’s drug received expedited review as one of… Read More

#News #Regulatory

Human cell
#Cell therapy #Clinical trial #Diabetes #Type 1 diabetes #Vertex

Vertex shares new data for stem cell-derived islet therapy in T1D

Vertex Pharmaceuticals has shared new Phase I/II data for zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy.  The FORWARD-101 clinical trial is investigating the treatment in people with type 1 diabetes (T1D) with impaired hypoglycaemic awareness and severe hypoglycaemic events (SHEs).  All… Read More

#News

Woman tests blood glucose level
#Diabetes #Immunotherapy #Type 1 diabetes #University of Queensland

Pioneering clinical trial of immunotherapy for type 1 diabetes

Researchers at The University of Queensland (UQ) have launched the first clinical trial of a potentially revolutionary immunotherapy drug to treat type 1 diabetes.  Professor Ranjeny Thomas from UQ’s Frazer Institute has led the development of a targeted immunotherapy drug, ASITI-201, which has been designed to rebalance… Read More

#News #Trending News

Pancreatic cells
#allogeneic cell therapies #Cell therapy #Diabetes #Sana Biotechnology #Type 1 diabetes

First evidence of cell transplant without immunosuppression

Positive results have been revealed from the first-in-human study transplanting an islet cell therapy into a patient with type 1 diabetes without the use of immunosuppression.  The study was investigating Sana Biotechnology’s UP421, an allogeneic primary islet cell therapy that has been engineered with… Read More

#News #Trending News

Stem cells
#Diabetes #Phase I trial #Pluripotent stem cells #Stem cells #Type 1 diabetes

Stem cell therapy cures type 1 diabetes

A type 1 diabetes patient has been successfully treated using chemically induced pluripotent stem-cell-derived islets (CiPSC islets). The Phase I trial is the first ever example of a person with the disease being treated using cells that were extracted from their own body. The… Read More

#Editor's Choice #News

Diabetes patient injecting insulin
#allogeneic cell therapies #Cell therapy #Sana Biotechnology #Stem cell transplant #Type 1 diabetes

Insulin independence without immunosuppression

Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). The study results were published in Cell Stem Cell, in a paper titled ‘Hypoimmune islets achieve insulin independence after allogeneic transplantation in a… Read More

#Editor's Choice #News

Woman uses Digital Glucose meter
#allogeneic cell therapies #Cell and gene therapy #Diabetes #FDA #Type 1 diabetes

FDA approves first cellular therapy for type 1 diabetes

The US Food and Drug Administration has approved CellTrans’ Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment of type 1 diabetes. Lantidra is approved for the treatment of adults with type 1 diabetes who are unable… Read More

#News #Trending News

Monoclonal antibodies
#Monoclonal antibodies #Tiziana Life Sciences #Type 1 diabetes

Tiziana develops intranasal antibody for type 1 diabetes

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. “With the FDA approval of the humanised anti-CD3 mAb TZIELD (teplizumab-mzwv injection) and then its subsequent announced acquisition of Provention Bio by Sanofi for… Read More

#News

#allogeneic cell therapies #Cell therapy #Collaboration #Diabetes #Imagine Pharma #LyGenesis #Partnership #Type 1 diabetes

Collaboration will advance cell therapies for type 1 diabetes

LyGenesis and Imagine Pharma have entered into a joint research collaboration to develop novel cell therapies for patients with type 1 diabetes. The research collaboration will use Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis' allogeneic cell therapy platform to develop therapies for type 1… Read More

#Business & Investment #News

Patient with type 1 diabetes
#Antibody #Diabetes #FDA #Type 1 diabetes #US

FDA approves first disease-modifying therapy for T1D

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for anti-CD3-directed antibody TZIELD (teplizumab-mzwv), the first immunomodulatory treatment for type 1 diabetes (T1D).   It is approved for intravenous use to delay the onset of stage 3 T1D in adult and paediatric patients aged eight years… Read More

#News #Regulatory

World Diabetes Day
#Diabetes #Drug discovery #Type 1 diabetes #Type 2 diabetes #World Diabetes Day

World Diabetes Day: Five drug discovery developments 

For World Diabetes Day, DDW’s Diana Spencer provides an overview of the latest innovations in the treatment of the disease. Here are 2022’s five most significant discoveries (in no particular order):  1. Human beta cell model Earlier this year, Human Cell Design, a biotechnology company focused on generating translational human… Read More

#Exclusive Content #News #Trending News